IN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca

Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - ...

Alliance News 12 August, 2021 | 12:56PM
Email Form Facebook Twitter LinkedIn RSS

Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Pretax loss widens to GBP22.6 million for six months that ended June from GBP13.3 million in the same period last year. Half-year revenue GBP5.8 million, up from GBP1.1 million. Proposes no interim dividend, unchanged.

"The first half of 2021 was marked by strong execution, highlighted by the first clinical data from our proprietary mRNAi GOLD platform that successfully translated results from pre-clinical models into humans. In addition to achieving positive clinical data from our platform, we started dosing patients in two wholly owned programs and added two new targets to our partnered pipeline," says Chief Executive Mark Rothera.

Interim revenue from collaborations is GBP5.8 million, up from GBP1.1 million last year, driven by collaboration with AstraZeneca PLC and Mallinckrodt PLC. Starts work on second undisclosed target with AstraZeneca, and on track to start work on five disease targets in next three years for cardiovascular, renal, metabolic, and respiratory diseases.

Current stock price: 604.88 pence

Year-to-date change: up 18%

By Josie O'Brien; josieobrien@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 10,946.00 GBX 0.29
Silence Therapeutics PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures